Home World News Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for... World News Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 574 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Reflections from our chief clinician: The essential role of our research... February 4, 2022 Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... December 19, 2022 Making the most of your ‘eureka’ moment: getting from the science... September 22, 2021 Death Rates from Lung Cancer will Fall Overall in the EU... March 6, 2023 Load more HOT NEWS RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... What’s happened to cancer services during the COVID-19 pandemic? Cleveland Clinic Launches Breast Cancer Vaccine Trial EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a...
